Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis
Mundipharma and Cidara Therapeutics announced that the European Commission (EC) has now adopted the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) recommendation to grant Orphan Drug Designation (ODD) to rezafungin, a novel, once-weekly echinocandin, for the treatment of invasive candidiasis (IC).